LegoChem Biosciences, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From LegoChem Biosciences, Inc.
Korea Drug Development Fund CEO H. Samuel Muk talks to Scrip how the government agency has evolved to support the Korean biopharma industry’s R&D and business development activities, as well as what key new projects are underway.
It is time for In Vivo's 15th annual Deals of the Year contest. We've selected 15 nominees across three categories – Top Alliance, Top Financing and Top M&A – and you get to pick the winners.
Scrip takes a look at the increasingly competitive landscape of Korean antibody-drug conjugate developers, which are now vying to catch up with their global rivals in the hot area.
Scrip wraps up major R&D and corporate developments for Korean biopharmas in 2022 and outlines what lies ahead for them in the new year.
- Contract Research, Toxicology Testing-CRO
- Drug Delivery
Drug Discovery Tools
- Large Molecule
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.